Expression of exon v6‐containing CD44 isoforms is related to poor prognosis of acute myelocytic leukemia

CD44 is a cell surface glycoprotein with a number of isoforms generated by alternative splicing of ten ‘variant’ exons in humans. Variant exon 6‐containing isoforms of CD44 (CD44v6) have been implicated in the metastatic potential of rat carcinoma cell lines. Human homologues of CD44v6 are expressed in several tumour types and are involved in their progression. In the present study, we examined the expression of CD44 mRNA in 20 acute myelocytic leukemias by semiquantitative RT–PCR analysis and assessed its prognostic value. In all leukemic cells the predominant isoform was the ‘standard’ form of CD44 (CD44H), and intense bands were found in eight cases. CD44v6 was expressed in 11 cases, although its levels and those of other variants containing exon v7 through to v10 were much lower than those of CD44H. Isoforms containing exon v4 or v5 could not be detected. The expression of CD44v6 correlated with the death rate from leukemia (p>0·05), but was not related to other risk factors. On the other hand, the intense expression of CD44H did not correlate with the prognosis of leukemia. CD44v6 thus appears to be a marker for the poor prognosis of acute myelocytic leukemia. Copyright © 1998 John Wiley & Sons, Ltd.

[1]  H. Kluin-Nelemans,et al.  A strong expression of CD44-6v correlates with shorter survival of patients with acute myeloid leukemia. , 1998, Blood.

[2]  H. Sorimachi,et al.  A Novel Ligand for CD44 Is Serglycin, a Hematopoietic Cell Lineage-specific Proteoglycan , 1995, The Journal of Biological Chemistry.

[3]  P. Schlag,et al.  Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins , 1995, The Lancet.

[4]  I. Stamenkovic,et al.  Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development , 1994, The Journal of experimental medicine.

[5]  J. Filmus,et al.  Activated ras and src induce CD44 overexpression in rat intestinal epithelial cells. , 1994, Oncogene.

[6]  C. Mackay,et al.  Expression and modulation of CD44 variant isoforms in humans , 1994, The Journal of cell biology.

[7]  G. Salles,et al.  Alternatively spliced CD44 transcripts in diffuse large-cell lymphomas: characterization and comparison with normal activated B cells and epithelial malignancies. , 1993, Blood.

[8]  F M van den Berg,et al.  Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. , 1993, Cancer research.

[9]  H. Müller-Hermelink,et al.  Differential expression of CD44 splice variants in intestinal- and diffuse-type human gastric carcinomas and normal gastric mucosa. , 1993, Cancer research.

[10]  P. Herrlich,et al.  A link between ras and metastatic behavior of tumor cells: ras induces CD44 promoter activity and leads to low-level expression of metastasis-specific variants of CD44 in CREF cells. , 1993, Cancer research.

[11]  P. Herrlich,et al.  Activated human lymphocytes and aggressive non-Hodgkin's lymphomas express a homologue of the rat metastasis-associated variant of CD44 , 1993, The Journal of experimental medicine.

[12]  P. Herrlich,et al.  Splicing choice from ten variant exons establishes CD44 variability. , 1993, Nucleic acids research.

[13]  P. Herrlich,et al.  Prevention of tumor metastasis formation by anti-variant CD44 , 1993, The Journal of experimental medicine.

[14]  P. Herrlich,et al.  A human homologue of the rat metastasis-associated variant of CD44 is expressed in colorectal carcinomas and adenomatous polyps , 1993, The Journal of cell biology.

[15]  J. Bell,et al.  Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[16]  I. Stamenkovic,et al.  CD44H regulates tumor cell migration on hyaluronate-coated substrate , 1992, The Journal of cell biology.

[17]  J. Bell,et al.  Multiple variants of the human lymphocyte homing receptor CD44 generated by insertions at a single site in the extracellular domain. , 1992, The Journal of biological chemistry.

[18]  S. Jalkanen,et al.  Lymphocyte CD44 binds the COOH-terminal heparin-binding domain of fibronectin , 1992, The Journal of cell biology.

[19]  I. Stamenkovic,et al.  Distinct effects of two CD44 isoforms on tumor growth in vivo , 1991, The Journal of experimental medicine.

[20]  Martin Hofmann,et al.  A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells , 1991, Cell.

[21]  M. Amiot,et al.  The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate‐bearing cells. , 1991, The EMBO journal.

[22]  P. Herrlich,et al.  Retardation of metastatic tumor growth after immunization with metastasis‐specific monoclonal antibodies , 1990, International journal of cancer.

[23]  D. S. Webb,et al.  LFA-3, CD44, and CD45: physiologic triggers of human monocyte TNF and IL-1 release. , 1990, Science.

[24]  I. Stamenkovic,et al.  CD44 is the principal cell surface receptor for hyaluronate , 1990, Cell.

[25]  K. Miyake,et al.  Monoclonal antibodies to Pgp-1/CD44 block lympho-hemopoiesis in long- term bone marrow cultures , 1990, The Journal of experimental medicine.

[26]  B. Haynes,et al.  Antibodies against the CD44 p80, lymphocyte homing receptor molecule augment human peripheral blood T cell activation. , 1990, Journal of immunology.

[27]  M. Telen,et al.  CD44--a molecule involved in leukocyte adherence and T-cell activation. , 1989, Immunology today.

[28]  William,et al.  Characterization of the class III collagen receptor, a phosphorylated, transmembrane glycoprotein expressed in nucleated human cells. , 1988, The Journal of biological chemistry.

[29]  W. Carter,et al.  Identification of multiple cell adhesion receptors for collagen and fibronectin in human fibrosarcoma cells possessing unique alpha and common beta subunits , 1987, The Journal of cell biology.

[30]  J. R. de los Toyos,et al.  Lymphocyte recognition of high endothelium: antibodies to distinct epitopes of an 85-95-kD glycoprotein antigen differentially inhibit lymphocyte binding to lymph node, mucosal, or synovial endothelial cells , 1987, The Journal of cell biology.

[31]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[32]  H. Weinstein,et al.  Acute nonlymphocytic leukemia. , 1985, Pediatric clinics of North America.

[33]  J. Adamson,et al.  Acute nonlymphocytic leukemia: expression in cells restricted to granulocytic and monocytic differentiation. , 1979, The New England journal of medicine.

[34]  E. Butcher,et al.  The regulation of lymphocyte traffic. , 1986, Current topics in microbiology and immunology.